TrialCardiovascular diabetology2013

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.

Martin Ridderstråle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.